Q1 2025 Evogene Ltd Earnings Call Transcript
Key Points
- Evogene Ltd (EVGN) successfully reduced its R&D expenses from $4.8 million in Q1 2024 to $3.2 million in Q1 2025, reflecting a strategic expense reduction plan.
- The company reported a significant increase in seed sales by Casterra, delivering 250 tons of castor seeds in Q1 2025, surpassing the total delivered in 2024.
- Evogene Ltd (EVGN) announced the acquisition of Lavie Bio's activities by ICL for $15.25 million, which is expected to generate value and cash flow.
- The company made substantial advancements in its ChemPass AI for pharma, enhancing its competitive advantage in drug discovery.
- Evogene Ltd (EVGN) has a strong cash position with $9.8 million in cash and short-term deposits as of March 31, 2025, excluding expected proceeds from asset sales.
- Total revenues for Q1 2025 decreased significantly to $2.4 million from $4.2 million in Q1 2024, primarily due to the absence of license fee payments received in the previous year.
- The company reported a net loss of $3 million for Q1 2025, although this was an improvement from the $3.8 million loss in Q1 2024.
- Evogene Ltd (EVGN) requires additional funding to advance Biomica's BMC128 to Phase II clinical trials, indicating potential financial constraints.
- The company is facing challenges in educating farmers to utilize its castor seed varieties effectively, which is a bottleneck for increasing sales.
- Evogene Ltd (EVGN) anticipates needing to further reduce expenses to extend its financial runway through 2026, highlighting ongoing financial pressures.
Ladies and gentlemen, welcome to Evogene's first-quarter 2025 results conference call. (Operator Instructions) As a reminder, this conference is being recorded, May 21, 2025.
Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene's management will constitute forward-looking statements that relate to future events. This presentation contains forward-looking statements relating to future events and Evogene may from time to time make other statements regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995 and other securities laws as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements.
Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should, planned, estimated, intend and potential or other words of similar meaning. We are using
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
